SCHEMBL5038147

SCHEMBL5038147

COc1cc([N+]#N)c(OC)c(-c2ccccc2)c1.F[B-](F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.42
PDE4B Q07343 3/20 0.40
PDE4A P27815 2/20 0.40
PDE4C Q08493 2/20 0.40
PDE4D Q08499 2/20 0.40
METAP2 P50579 1/20 0.40
IKBKB O14920 1/20 0.39
ABL1 P00519 2/20 0.38
ABCB1 P08183 2/20 0.38
BCR P11274 2/20 0.38
KMT2A Q03164 1/20 0.36
PIN1 Q13526 1/20 0.35
CYP1A1 P04798 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2E1 P05181 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C8 P10632 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2A6 P11509 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8501250 0.78 PIN1 (0.47) BACE1ABL1ABCB1BCRKMT2A
Hydrochloric Acid SCHEMBL8497285 0.76 PIN1 (0.46) BACE1ABL1ABCB1BCRKMT2A
SCHEMBL5035315 0.76 CA2 (0.37) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5045304 0.71 BACE1 (0.48) BACE1PDE4BPDE4APDE4CPDE4D
SCHEMBL29106531 0.69 ALDH1A1 (0.39) BACE1KMT2ACYP2A6PTPN1ALDH1A1
SCHEMBL224709 0.69 GSTP1 (0.53) CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8
SCHEMBL28789773 0.69 IKBKB (0.65) BACE1PDE4BPDE4APDE4CPDE4D
SCHEMBL11409076 0.68 CA12 (0.48) KMT2ACYP1A1CYP1A2CYP2E1CYP3A4
SCHEMBL12341703 0.68 SQOR (0.55) BACE1METAP2ABL1ABCB1BCR
SCHEMBL29946227 0.68 BACE1 (0.44) BACE1PDE4BPDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962863-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 Conforma Therapeutics Corporation (US) 2008-09-03 EP disclosed
WO-2007075572-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-07-05 WO disclosed
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 HSP90AB1, HSP90AA1, HSP90AB2P BACE1 3537/4885PDE4B 2098/4885PDE4A 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.